JP6790222B2 - エストロゲン受容体ダウンレギュレーターとしての置換インドール化合物 - Google Patents

エストロゲン受容体ダウンレギュレーターとしての置換インドール化合物 Download PDF

Info

Publication number
JP6790222B2
JP6790222B2 JP2019500726A JP2019500726A JP6790222B2 JP 6790222 B2 JP6790222 B2 JP 6790222B2 JP 2019500726 A JP2019500726 A JP 2019500726A JP 2019500726 A JP2019500726 A JP 2019500726A JP 6790222 B2 JP6790222 B2 JP 6790222B2
Authority
JP
Japan
Prior art keywords
group
groups
μmol
mmol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019500726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512550A (ja
JP2019512550A5 (cg-RX-API-DMAC10.html
Inventor
剣宇 陸
剣宇 陸
照中 丁
照中 丁
利紅 胡
利紅 胡
輝君 賀
輝君 賀
曙輝 陳
曙輝 陳
加強 董
加強 董
鉄林 王
鉄林 王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luoxin Pharmaceutical Shanghai Co Ltd
Shandong Luoxin Pharmaceutical Group Co Ltd
Original Assignee
Luoxin Pharmaceutical Shanghai Co Ltd
Shandong Luoxin Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luoxin Pharmaceutical Shanghai Co Ltd, Shandong Luoxin Pharmaceutical Group Co Ltd filed Critical Luoxin Pharmaceutical Shanghai Co Ltd
Publication of JP2019512550A publication Critical patent/JP2019512550A/ja
Publication of JP2019512550A5 publication Critical patent/JP2019512550A5/ja
Application granted granted Critical
Publication of JP6790222B2 publication Critical patent/JP6790222B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
JP2019500726A 2016-03-25 2017-03-24 エストロゲン受容体ダウンレギュレーターとしての置換インドール化合物 Active JP6790222B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610180518 2016-03-25
CN201610180518.7 2016-03-25
CN201610867918.5 2016-09-29
CN201610867918 2016-09-29
PCT/CN2017/078139 WO2017162206A1 (zh) 2016-03-25 2017-03-24 作为雌激素受体降解剂的吲哚并取代哌啶类化合物

Publications (3)

Publication Number Publication Date
JP2019512550A JP2019512550A (ja) 2019-05-16
JP2019512550A5 JP2019512550A5 (cg-RX-API-DMAC10.html) 2019-11-28
JP6790222B2 true JP6790222B2 (ja) 2020-11-25

Family

ID=59899253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019500726A Active JP6790222B2 (ja) 2016-03-25 2017-03-24 エストロゲン受容体ダウンレギュレーターとしての置換インドール化合物

Country Status (11)

Country Link
US (1) US10519143B2 (cg-RX-API-DMAC10.html)
EP (1) EP3434668B1 (cg-RX-API-DMAC10.html)
JP (1) JP6790222B2 (cg-RX-API-DMAC10.html)
KR (1) KR102111792B1 (cg-RX-API-DMAC10.html)
CN (1) CN108884035B (cg-RX-API-DMAC10.html)
AU (1) AU2017239348B2 (cg-RX-API-DMAC10.html)
CA (1) CA3018801C (cg-RX-API-DMAC10.html)
ES (1) ES2821407T3 (cg-RX-API-DMAC10.html)
RU (1) RU2722441C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201808363TA (cg-RX-API-DMAC10.html)
WO (1) WO2017162206A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032627B (zh) 2017-09-25 2023-10-20 罗欣健康科技发展(北京)有限公司 一种雌激素受体抑制剂的晶型及其制备方法
AU2019321588C1 (en) 2018-08-17 2026-05-14 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
EP3889136B1 (en) * 2018-11-28 2024-12-18 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor
AU2019400398B2 (en) * 2018-12-17 2024-10-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Estrogen receptor antagonist
CN116891461B (zh) * 2022-03-30 2026-05-15 罗欣药业(上海)有限公司 一种serd中间体的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US9499538B2 (en) * 2012-03-20 2016-11-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
SG11201607334YA (en) * 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
MA39740A (fr) * 2014-03-13 2017-01-18 Hoffmann La Roche Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes

Also Published As

Publication number Publication date
CA3018801A1 (en) 2017-09-28
RU2018135203A3 (cg-RX-API-DMAC10.html) 2020-04-27
RU2722441C2 (ru) 2020-06-01
CN108884035A (zh) 2018-11-23
US20190106414A1 (en) 2019-04-11
ES2821407T3 (es) 2021-04-26
SG11201808363TA (en) 2018-10-30
US10519143B2 (en) 2019-12-31
EP3434668B1 (en) 2020-08-26
RU2018135203A (ru) 2020-04-27
EP3434668A4 (en) 2019-08-14
ES2821407T8 (es) 2022-02-02
CN108884035B (zh) 2020-03-13
WO2017162206A1 (zh) 2017-09-28
EP3434668A1 (en) 2019-01-30
KR102111792B1 (ko) 2020-05-18
AU2017239348B2 (en) 2020-03-12
JP2019512550A (ja) 2019-05-16
CA3018801C (en) 2020-06-23
KR20180128456A (ko) 2018-12-03
HK1256936A1 (zh) 2019-10-04
AU2017239348A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
JP7290638B2 (ja) Wee1阻害剤としての大環状化合物及びその使用
JP6717457B2 (ja) Wee1阻害剤としての1,2−ジヒドロ−3H−ピラゾロ[3,4−d]ピリミジン−3−オン誘導体
CN115003295B (zh) 具有雌激素受体降解活性的新型色满衍生物及其用途
CN110963994B (zh) 异吲哚啉类化合物、其制备方法、药物组合物及用途
JP2024505735A (ja) 置換されたピリダジンフェノール系誘導体
JP7237010B2 (ja) Hdac6選択的阻害剤およびその製造方法と使用
CN110139863B (zh) 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
KR102111792B1 (ko) 에스트로겐 수용체 하향 조절제로서의 치환된 인돌 화합물
JP6836693B2 (ja) A2a受容体アンタゴニストとしての縮合環誘導体
JP2019519606A (ja) チオフェン化合物、その合成方法及び医療における応用
BR112017009012B1 (pt) Derivados de anel benzo de seis membros como inibidor de dpp-4 e uso dos mesmos
CN117466870A (zh) 苯并七元环类双功能化合物及其应用
CN112168824B (zh) 阿朴菲类化合物的应用
JP6951418B2 (ja) 抗hcmvウイルス化合物
CN116438177B (zh) 靶向嵌合化合物、含其的药物组合物及其制备方法和用途
CN100502846C (zh) 3,4,5-三取代的苯丙烯类衍生物及其制备方法和用途
HK1256936B (en) Substituted-indole compounds as estrogen receptor down-regulators
WO2019120198A1 (zh) 一类喹啉衍生物
RU2772274C2 (ru) Селективные ингибиторы hdac6, способ их получения и их применение
CA3049834C (en) Hdac6 selective inhibitors, preparation method therefor, and application thereof
JPH07500571A (ja) Pcpレセプター・リガンドおよびその用途
HK40080061B (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
CN120383593A (zh) 一种识别α-突触核蛋白聚集体的化合物及其用途
HK40022836A (en) Macrocyclic compound as a wee1 inhibitor and applications thereof
HK40022836B (en) Macrocyclic compound as a wee1 inhibitor and applications thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191015

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20191015

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20191217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201104

R150 Certificate of patent or registration of utility model

Ref document number: 6790222

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250